Blue test tubes arranged in a line, disappearing into the background

Drug news

Shingrix approved in EU and Japan for the prevention of shingles (herpes zoster) and post-herpetic neuralgia. - GSK.

Read time: 1 mins

Last updated:24th Mar 2018

Published:24th Mar 2018

Source: Pharmawand

GlaxoSmithKline announced that the European Commission has approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN) in adults aged 50 years or older. The GSK said the Japanese Ministry of Health, Labour and Welfare has also approved Shingrix for the prevention of shingles in adults aged 50 years or older.

It described Shingrix as a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses. In Japan the vaccine is registered to the Japan Vaccine Co., Ltd., a joint venture of GlaxoSmithKline and Daiichi Sankyo Co., Ltd.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approves Hympavza (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age with severe hemophilia A or severe hemophilia B

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavza (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A (congenital factor VIII [FVIII] deficiency, FVIII <1%) without FVIII inhibitors or severe hemophilia B (congenital factor IX [FIX] deficiency, FIX <1%) without FIX inhibitors

1 mins

Drug news

Zai Lab and Pfizer announced a strategic collaboration for Xacduro (sulbactam-durlobactam) in mainland China

Zai Lab and Pfizer announced a strategic collaboration for the novel antibacterial drug Xacduro (sulbactam-durlobactam) in mainland China. Pfizer’s affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for Xacduro in mainland China

1 min

Drug news

Positive phase II study results of once-monthly efimosfermin alfa, in participants with stage F2/F3 fibrosis due to MASH

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH)

1 min

See all news